Jonathan Havens of Saul Ewing Arnstein & Lehr LLP to talk about what the US FDA’s approval of GW Pharma’s Epidiolex CBD-derived product.
Havens described what will happen to Epidiolex now – including a possible rescheduling by the US Drug Enforcement Administration.
For more about Epidolex.
For more about Saul Ewing Arnstein & Lehr LLP.
For more about Jonathan Havens.
Earlier this year, Greece became the latest EU country to make medical cannabis products available to patients. In February 2024,...
Curaleaf has finalised its $16m acquisition of Canadian cannabis producer Northern Green Canada (NGC), helping the company secure its foothold...
Earlier this year, Greece became the latest EU country to make medical cannabis products available to patients. In February 2024,...
Curaleaf has finalised its $16m acquisition of Canadian cannabis producer Northern Green Canada (NGC), helping the company secure its foothold...
US Rep. Earl Blumenauer, founding co-chair of the Congressional Cannabis Caucus, said he believes Saturday was the ‘last 4/20 celebration...
New York’s Governor Kathy Hochul has announced a new plan to ‘finally put an end to the chaos’ of unlicensed...
Cannabis criminalization ‘does little to curtail use’ according to a new study, which found only a 1.1% difference in regular...
Release is launching a vital initiative. We are launching the #ReleaseOurMeds campaign to protect the rights of patients to access...
Kentucky citizens could now have access to medical cannabis this year as the state’s Governor Andy Beshear announced plans to...
The head of the US Food and Drug Administration (FDA), Robert Califf, told elected officials this week that he believes...
Germany’s cannabis decriminalisation takes effect On April 1, 2024, Germany’s long-fought CanG bill came into effect, seeing thousands of supporters...
The UK’s medical cannabis market is continuing to develop at pace, and a major reason behind this growth has been...
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
